News | January 30, 2025
Piramal Pharma Q3 FY25 revenue up 13%
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Q3 FY25 revenue up 24% to Rs 3,230 crore
EBITDA margins expand to 31.3%
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
Subscribe To Our Newsletter & Stay Updated
